How New Oral Androgen Receptor Pathway Agents Have Changed the Way Prostate Cancer is Treated

January 19, 2013 by  
Filed under Prostate Cancer News

The way early-stage prostate cancer is treated is different from how late-stage cases are treated. The latter often referred to as metastatic prostate cancer or that which has become resistant to hormonal therapies. In other words, they are resistant to androgen therapies.

Anna Azvolinsky PhD, published an article recently at Onclive, an oncology website describing how the approval of two new oral agents, abiraterone acetate (Zytiga) and Enzalutamide (Xtandi) is changing the way metastatic prostate cancer is treated.

The new treatments have been effective and their overall impacts do change urology practices for this disease. Below is a highlight on the online article published January 18, 2013:

The treatment of late-stage prostate cancer is shifting. With the approval of two new oral agents, abiraterone acetate (Zytiga) in April 2011 and enzalutamide (Xtandi) in August 2012, there are now options for men with metastatic prostate cancer who have progressed after chemotherapy treatment with docetaxel where there were none just two years ago. Since its initial approval, abiraterone has also been approved by the FDA for the use of abiraterone in chemotherapy-naïve patients with metastatic prostate cancer. Enzalutamide is also being tested in this patient population; a phase III trial is ongoing.

The reason for the shift? Research over the past 10 years has shown that metastatic prostate cancer tumors that are resistant to hormonal (androgen)- deprivation therapies still rely on androgen receptor (AR) pathways for growth. “Until this decade, we had assumed that tumors from [surgically or medically castrated patients who stopped responding to hormonal treatments] were no longer reliant on hormones for their growth and progression,” said Joshi J. Alumkal, MD, assistant professor of Medicine at the Oregon Health & Science University in Portland.

Next-Generation Androgen Receptor Signaling Agents

There are several mechanisms by which prostate tumors hijack androgen signaling to fuel cancer growth. Some castration-resistant prostate cancer (CRPC) tumors are able to make testosterone and androgen precursors. These tumors also amplify ARs on prostate cancer cells or develop mutations in AR genes. The next-generation androgen-targeting therapies, abiraterone and enzalutamide, target these mechanisms.

“Abiraterone and enzalutamide are proof that at least in some patients, male hormones still matter and they are promoting prostate cancer growth. Those are the 50% of patients who respond [to these new agents], at least temporarily, and who may derive an overall survival benefit,” said Alumkal.

The two drugs have different mechanisms of action. Abiraterone works by inhibiting CYP17, an enzyme necessary to make a precursor of testosterone in the testes, adrenal glands, and within the prostate tumor itself. Enzalutamide is a second-generation oral antiandrogen that binds to the androgen receptor, inhibiting the interaction of testosterone to its receptor.


“Enzalutamide is selective—it works particularly well in tumors in which the androgen receptor is overactive, such as through amplification,” said Andrew J. Armstrong, MD, MSc, co-leader of the Genitourinary Oncology Research program at Duke University School of Medicine in Durham, North Carolina.

Other novel hormonal agents in development include orteronel (TAK700), another oral nonsteroidal selective inhibitor of androgen synthesis that targets the same enzyme as abiraterone. The oral drug is being tested in phase III trials in patients with metastatic CRPC both before and after treatment with chemotherapy.

Another novel oral agent, ODM-201, has the same mechanism of action as enzalutamide, and thus interacts with the AR. The drug has shown high response rates in a phase I/II first-in-human trial presented at this year’s European Society for Medical Oncology (ESMO) Congress.

 Management of Prostate Cancer in Urology Practices

As abiraterone, enzalutamide, and other oral androgen-targeting therapies become the standard of care, it is likely that more urologists will be treating patients with advanced prostate cancer and that these patients will remain in the care of their urologists longer, through the progression of their cancer.

This trend of prostate cancer management within urology practices will likely continue as these newer agents move into the nonmetastatic setting. “As we see the data emerge in the nonmetastatic setting, you may see more urologists consider using these drugs because they appear quite safe,” said Armstrong.

Armstrong emphasized that there are serious side effects of these agents that urologists may not wish to manage, such as heart failure, liver toxicity, muscle fatigue, risk of seizure, and drug interactions with other medications. But with proper training, he believes urologists can manage the toxicities.

Click here to read the full online publication

Conclusively, treatment of metastatic prostate cancer has received significant boost over the last couple of months since the introduction of Abiraterone and Enzalutamide. This fact has been acknowledged by many experts as the above article has shown.

These drugs have shown to be effective in helping to treat prostate cancer at the late stage with improved result.

The combination of these two drugs may prove to yield better results but more thorough research still needs to prove if that are really possible.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)

  1. Androgen -Independent Prostate Cancer – Information That SHOULD be Useful to You
  2. Review on New Drugs that Targets Androgen Production in Prostate Cancer
  3. Side Effects Of Prostate Cancer Androgen Hormone Therapy and Androgen Independent Prostate Cancer
  4. Mt1 Melatonin Receptor Prostate Colon Cancer
  5. Scottish Prostate Cancer Patients Now To Be Treated With Abiraterone
  6. Side Effects Of Prostate Cancer Androgen Hormone Therapy
  7. About New Report on Hormone Refractory (Castration Resistant, Androgen-independent) Prostate Cancer – Pipeline Review H2, 2012″
  8. Study Suggests Androgen Deprivation May Do More Harm than Good in Men with Prostate Cancer
  9. Prostate Cancer 2012: Recent and Possible Future Advances in Prostate Cancer Treatments
  10. Bladder Cancer Patients Can benefit from Anti – Androgen Treatment as Prostate Cancer Patients
  11. Radical Prostatectomy Superior to Androgen Deprivation Therapy in Treating Localized Prostate Cancer
  12. New Oral Drug Helps in Delaying the Spread of Prostate Cancer
  13. How Hormone Refractory Prostate Cancer (HRPC) is Treated
  14. Prostate Cancer Androgen Hormone Therapy Side Effects
  15. Abiraterone Prostate Cancer – Interesting Facts about This Drug

Speak Your Mind

Tell us what you're thinking... !